|Dr. Amit Kumar Ph.D.||Chairman, Pres & CEO||693.03k||N/A||1964|
|Mr. Michael J. Catelani||COO, CFO & Corp. Sec.||281.92k||N/A||1967|
|Mr. John Roop||Sr. VP of Engineering||N/A||N/A||1950|
Anixa Biosciences, Inc., a cancer-focused biotechnology company, develops both diagnostics and therapeutics to detect cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs, which genetically engineer a patient's own immune cells to fight cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Anixa Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.